Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Som D Mukherjee

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
JACC. Cardiooncology|August 16, 2021
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I TrialDarryl P Leong, Tammy Cosman, Muhammad M Alhussein, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Cancer Immunology Research|September 9, 2016
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate CancerElizabeth Scheid, Pierre Major, Alain Bergeron, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
Current Oncology (Toronto, Ont.)|April 26, 2024
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for ImprovementSandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, et al.
Breast Cancer Research and Treatment|April 28, 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32Ana Elisa Lohmann, Mira F Liebman, William Brien, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
JACC. Cardiooncology|August 16, 2021
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I TrialDarryl P Leong, Tammy Cosman, Muhammad M Alhussein, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Cancer Immunology Research|September 9, 2016
Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate CancerElizabeth Scheid, Pierre Major, Alain Bergeron, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
Current Oncology (Toronto, Ont.)|April 26, 2024
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for ImprovementSandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, et al.
Breast Cancer Research and Treatment|April 28, 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32Ana Elisa Lohmann, Mira F Liebman, William Brien, et al.
Pageof 6